Cargando…

Dolutegravir/rilpivirine for the treatment of HIV-1 infection

Much progress has been made in the development of antiretroviral therapies (ARTs) for HIV-1 infection. Beginning a little over a decade ago, single tablet combination regimens (STRs) became available, and subsequently, newer STR formulations with improved safety profiles have emerged. Recently, ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dowers, Ellen, Zamora, Francis, Barakat, Lydia Aoun, Ogbuagu, Onyema
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220428/ https://www.ncbi.nlm.nih.gov/pubmed/30464642 http://dx.doi.org/10.2147/HIV.S157855

Ejemplares similares

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
por: Zamora, Francis J, et al.
Publicado: (2019)

Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study
por: Palacios, Rosario, et al.
Publicado: (2018)

599. Expanding HIV Training in Internal Medicine Residency Program: A Prospect to Meet the HIV Workforce Demand
por: Barakat, Lydia, et al.
Publicado: (2018)

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection
por: Mehta, Rashmi, et al.
Publicado: (2018)

High HIV Detection in a Tertiary Facility in Liberia: Implications and Opportunities
por: Ogbuagu, Onyema, et al.
Publicado: (2021)

2541. Steady-state PK of Fixed Dose Dolutegravir+Rilpivirine in Hemodialysis
por: Gupta, Samir K, et al.
Publicado: (2023)

1261. Alarming High Rate of HIV Detected by Testing and Prevention Opportunities: Observations From the Largest HIV Program in Liberia
por: Ogbuagu, Onyema, et al.
Publicado: (2019)

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
por: Dueñas-Gutiérrez, Carlos, et al.
Publicado: (2023)

2485. Real-world Experience with Dolutegravir Plus Rilpivirine Two-Drug Regimen
por: Ward, Douglas, et al.
Publicado: (2019)

Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
por: Troya, Jesús, et al.
Publicado: (2022)

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients
por: Riccardi, Niccolò, et al.
Publicado: (2019)

1328. Post-War and Post-Ebola HIV Care Continuum in a Liberian Academic Center: Fresh Insights and Trends Over 5-Year Period
por: Watchekwa, Ian, et al.
Publicado: (2019)

2483. Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States
por: Pierone, Gerald, et al.
Publicado: (2019)

Comparison of Time to Viral Suppression Among Treatment-Naïve HIV-Infected Adults Initiating Combination Antiretroviral Therapy by Antiretroviral Regimen Class
por: Jacobson, Karen, et al.
Publicado: (2017)

HIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief report
por: Ogbuagu, Onyema, et al.
Publicado: (2023)

Correction: HIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief report
por: Ogbuagu, Onyema, et al.
Publicado: (2023)

Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health
por: McComsey, Grace A., et al.
Publicado: (2018)

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
por: Capetti, Amedeo F., et al.
Publicado: (2016)

The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet
por: Mehta, Rashmi, et al.
Publicado: (2020)

An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients
por: Putcharoen, Opass, et al.
Publicado: (2013)

Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection
por: Bernardini, Claudia, et al.
Publicado: (2013)

Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2022)

The role of dolutegravir in the management of HIV infection
por: Miller, Misty M, et al.
Publicado: (2015)

Extensive Central Nervous System Cryptococcal Disease Presenting as Immune Reconstitution Syndrome in a Patient with Advanced HIV: Report of a Case and Review of Management Dilemmas and Strategies
por: Ogbuagu, Onyema, et al.
Publicado: (2014)

Efficacy of switching to dolutegravir plus rilpivirine, the small-tablet regimen, in patients with dysphagia: two case reports
por: Suzuki, Takefumi, et al.
Publicado: (2017)

Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
por: Ogbuagu, Onyema, et al.
Publicado: (2018)

1582. Dolutegravir/Rilpivirine STR Switch Study in Persons with HIV-1 and Chronic Kidney Disease: 48-week Assessment of Viral Suppression, Treatment Adherence and Quality of Life
por: Kwakwa, Helena, et al.
Publicado: (2023)

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS
por: Taha, Huda, et al.
Publicado: (2015)

Curbing Ebola infections among healthcare workers in West Africa: unconventional strategies needed
por: Ogbuagu, Onyema Eberechukwu, et al.
Publicado: (2014)

Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2
por: Llibre, Josep M., et al.
Publicado: (2022)

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
por: Fernandez, Cristina, et al.
Publicado: (2019)

HIV–1 resistance to dolutegravir: update and new insights
por: Wainberg, Mark A, et al.
Publicado: (2015)

Implementing a Comprehensive Hepatitis C Virus (HCV) Clinic Within a Human Immunodeficiency Virus Clinic: A Model of Care for HCV Microelimination
por: Rizk, Christina, et al.
Publicado: (2019)

Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus–infected patients compared to non-nucleoside and protease inhibitor–based regimens in a real-world clinical setting: A retrospective cohort study
por: Jacobson, Karen, et al.
Publicado: (2018)

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV
por: Kandel, Christopher E, et al.
Publicado: (2015)

New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
por: Patel, Nimish, et al.
Publicado: (2012)

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients
por: Zhang, Jianping, et al.
Publicado: (2015)

Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda
por: Kambutse, Immaculate, et al.
Publicado: (2018)

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
por: Suárez-García, Inés, et al.
Publicado: (2023)

Race and ethnicity do not impact eligibility for remdesivir: A single-center experience
por: Pischel, Lauren, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hai46ull432hvi3q65411joqp8